Zimmer Biomet Q1 2026 sales rise 9.3% to $2.087 billion; adjusted EPS guidance raised
Zimmer Biomet reported first-quarter 2026 net sales of $2.087 billion, up 9.3% from the prior year, and diluted earnings per share of $1.22, up 34.1%. The company raised its full-year 2026 adjusted diluted EPS guidance to $8.40-$8.55 from $8.30-$8.45, while its reported revenue change guidance of 2.5%-4.5% was unchanged. The company's goodwill impairment assessment is not yet complete, and any charge would change first-quarter GAAP net earnings.
Key points
- Net sales $2.087 billion, up 9.3% reported and 2.9% on an organic constant currency basis
- Diluted EPS $1.22 versus $0.91; adjusted diluted EPS $2.09, up 15.5%
- 2026 adjusted diluted EPS guidance raised to $8.40-$8.55 from $8.30-$8.45
- Operating cash flow $359.4 million and free cash flow $245.9 million; $250 million of share repurchases in the quarter
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.